​

Terns Pharmaceuticals (TERN) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

TERN Stock Forecast

Terns Pharmaceuticals (TERN) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $20.00, with a high of $20.00 and a low of $20.00. This represents a 792.86% increase from the last price of $2.24.

- $4 $8 $12 $16 $20 High: $20 Avg: $20 Low: $20 Last Closed Price: $2.24

TERN Stock Rating

Terns Pharmaceuticals stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (81.82%), 2 Hold (18.18%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 2 9 Strong Sell Sell Hold Buy Strong Buy

TERN Price Target Upside V Benchmarks

TypeNameUpside
StockTerns Pharmaceuticals792.86%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$18.67
Last Closing Price$2.24$2.24$2.24
Upside/Downside--733.48%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25253--10
Mar, 25253--10
Feb, 25252--9
Jan, 25252--9
Dec, 24252--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 03, 2024Jay OlsonOppenheimer$20.00$6.36214.47%792.86%
Sep 16, 2024Etzer DaroutBMO Capital$26.00$8.96190.18%1060.71%
Aug 21, 2024Graig SuvannavejhMizuho Securities$10.00$7.7928.37%346.43%
Mar 15, 2024Etzer DaroutBMO Capital$19.00$7.20163.89%748.21%
Dec 29, 2022H.C. Wainwright$7.00$9.60-27.08%212.50%
Dec 20, 2022Goldman Sachs$14.00$7.7879.95%525.00%
Sep 27, 2022Corinne JenkinsGoldman Sachs$9.00$4.9282.93%301.79%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 27, 2025William BlairMarket Performinitialise
Dec 03, 2024OppenheimerOutperformOutperformhold
Sep 10, 2024BMO CapitalOutperformOutperformhold
Sep 10, 2024JMP SecuritiesOutperformOutperformhold
Aug 10, 2023NeedhamNeutralNeutralhold
Jun 28, 2023JMP SecuritiesMarket OutperformMarket Outperformhold
Feb 07, 2023UBSBuyinitialise
Dec 29, 2022CitigroupNeutralNeutralhold
Dec 20, 2022Goldman SachsBuyBuyhold
Sep 27, 2022Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.27$-1.12----
Avg Forecast$-1.33$-1.19$-1.32$-1.45$-1.67$-1.45
High Forecast$-1.28$-1.17$-1.18$-1.25$-1.52$-1.45
Low Forecast$-1.41$-1.23$-1.40$-1.63$-1.96$-1.45
Surprise %-4.51%-5.88%----

Revenue Forecast

$0 $7M $14M $21M $28M $35M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$1.95M$1.71M$2.40M$11.53M$32.00M
High Forecast-$1.95M$1.71M$2.40M$11.53M$32.00M
Low Forecast-$1.95M$1.71M$2.40M$11.53M$32.00M
Surprise %------

Net Income Forecast

$-140M $-128M $-116M $-104M $-92M $-80M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-90.21M$-88.85M----
Avg Forecast$-95.79M$-85.54M$-91.82M$-102.55M$-124.02M$-103.33M
High Forecast$-91.37M$-83.40M$-84.17M$-89.04M$-108.56M$-103.33M
Low Forecast$-100.21M$-87.67M$-99.47M$-116.05M$-139.48M$-103.33M
Surprise %-5.82%3.88%----

TERN Forecast FAQ

Is Terns Pharmaceuticals stock a buy?

Terns Pharmaceuticals stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Terns Pharmaceuticals is a favorable investment for most analysts.

What is Terns Pharmaceuticals's price target?

Terns Pharmaceuticals's price target, set by 11 Wall Street analysts, averages $20 over the next 12 months. The price target range spans from $20 at the low end to $20 at the high end, suggesting a potential 792.86% change from the previous closing price of $2.24.

How does Terns Pharmaceuticals stock forecast compare to its benchmarks?

Terns Pharmaceuticals's stock forecast shows a 792.86% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Terns Pharmaceuticals over the past three months?

  • April 2025: 20.00% Strong Buy, 50.00% Buy, 30.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 20.00% Strong Buy, 50.00% Buy, 30.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 22.22% Strong Buy, 55.56% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.

What is Terns Pharmaceuticals’s EPS forecast?

Terns Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.32, marking a 17.86% increase from the reported $-1.12 in 2024. Estimates for the following years are $-1.45 in 2026, $-1.67 in 2027, and $-1.45 in 2028.

What is Terns Pharmaceuticals’s revenue forecast?

Terns Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $1.71M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $2.4M, followed by $11.53M for 2027, and $32M for 2028.

What is Terns Pharmaceuticals’s net income forecast?

Terns Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-91.819M, representing an 3.34% increase from the reported $-88.853M in 2024. Projections indicate $-103M in 2026, $-124M in 2027, and $-103M in 2028.